June 5, 2024 7:31am

Another way of saying, don't do buying/selling without thinking or tracking RMi’s post/updates; keep a buy ticket in one hand and a finger on the sell button

News: Cellectis (CLLS) the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its P1/2 candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL).

Late breaking: ADP reported that companies added 152,000 jobs in May, fewer than the downwardly revised 188,000 in April and below consensus estimate for 175,000.

A daily analytic read-out from RMi is constructed by specific warnings of challenging share pricing situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and markets doesn't necessarily translate into actual trading in the today’s market session.

 

Wednesday: The pre-open Dow futures are UP +0.7% or (+67 points), the S&P futures are UP +0.25% or (+13 points) as the Nasdaq futures are UP +0.48% or (+90 points)

Stock futures are inched higher Wednesday waiting for private payroll data,

European stocks were higher,

Asia Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday: The Dow closed UP +140.26 points or +0.36%, the S&P closed UP +7.94 points or +0.15% while the Nasdaq closed UP +28.38 points or +0.17%

Economic Data Docket: MBA Mortgage Applications, week ended May 31 (-5.7%); ADP private payrolls, May (+174,000 expected, +192,000 prior); S&P global US Services PMI, May final (54.8 prior), S&P Global US composite PMI, May final (54.5 prior); ISM services index, May (50.9 expected, 49.4 prior); ISM services prices paid, May (59.2)

From the news in the title: Cellectis (CLLS) …

  • UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in BALLI-01, a P1/2 open-label dose-escalation and dose-expansion study, designed to evaluate the safety and clinical activity of UCART22 in patients with relapse/refractory ALL.
  • ALL represents 12% of all leukemia cases, progresses rapidly, and is typically fatal within weeks or months if left untreated1. In 2024, the 10-year prevalence is estimated at 1.9 in 100,000 persons in the European Union (EU).

 

Q2/24: 

June – 1 positive and 1 negative closes

  • May – 1 holiday, 11 positive and 11 negative closes
  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Yet again, I am passing on forecasting the daily indications is focused on inflation-oriented ADP private payrolls report and US services and global PMI “numbers” the aftermarket fluctuated as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE: What I wrote Monday, still stands: “Be careful, it's not a great time to be adding exposure; however, there are some glaring overbought and a some oversold.”

  • The ISM services index is on tap Wednesday morning as markets fear that U.S. and global economic growth is slowing too much.
  • The stock market rally had a mixed session Tuesday. The major indexes rose slightly but small caps fell solidly.
  •  

Cell and gene therapy sector breadth was decidedly weak with the small-cap Russell 2000 falling 1.25%.

This is a tricky market. The Nasdaq and S&P 500 are holding near highs, above their 21-day moving average. But there's a lot of underlying weakness, including in leading stocks. <IBD>

  • So, investors should be cautious about making many new buys until the market shows more clarity.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.